MA48798B1 - Procédé de production d'ozanimod - Google Patents

Procédé de production d'ozanimod

Info

Publication number
MA48798B1
MA48798B1 MA48798A MA48798A MA48798B1 MA 48798 B1 MA48798 B1 MA 48798B1 MA 48798 A MA48798 A MA 48798A MA 48798 A MA48798 A MA 48798A MA 48798 B1 MA48798 B1 MA 48798B1
Authority
MA
Morocco
Prior art keywords
ozanimod
production process
new
polimop
formula
Prior art date
Application number
MA48798A
Other languages
English (en)
Other versions
MA48798A (fr
Inventor
Márta Porcs-Makkay
Gyula Simig
Eniko Molnár
Balázs Volk
László Szlávik
Éva Szabó
Judit Halász
János Pethö
Original Assignee
Egyt Gyogyszervegyeszeti Gyar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar
Publication of MA48798A publication Critical patent/MA48798A/fr
Publication of MA48798B1 publication Critical patent/MA48798B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/07—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un nouveau procédé pour la préparation d'ozanimod de formule et de sels d'addition d'acide, par le biais de nouveaux intermédiaires et d'une nouvelle forme polimop à base d'ozanimod.
MA48798A 2017-05-22 2018-05-18 Procédé de production d'ozanimod MA48798B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP1700216 2017-05-22
PCT/HU2018/050019 WO2018215807A1 (fr) 2017-05-22 2018-05-18 Procédé de production d'ozanimod

Publications (2)

Publication Number Publication Date
MA48798A MA48798A (fr) 2020-04-08
MA48798B1 true MA48798B1 (fr) 2023-10-31

Family

ID=89720175

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48798A MA48798B1 (fr) 2017-05-22 2018-05-18 Procédé de production d'ozanimod

Country Status (12)

Country Link
US (1) US12459907B2 (fr)
EP (1) EP3630738B1 (fr)
CN (1) CN110997645B (fr)
EA (1) EA201992421A1 (fr)
ES (1) ES2960051T3 (fr)
HR (1) HRP20231308T1 (fr)
HU (1) HUE064642T2 (fr)
MA (1) MA48798B1 (fr)
PL (1) PL3630738T3 (fr)
PT (1) PT3630738T (fr)
SI (1) SI3630738T1 (fr)
WO (1) WO2018215807A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019094409A1 (fr) * 2017-11-07 2019-05-16 Teva Pharmaceuticals International Gmbh Sels et formes à l'état solide d'ozanimod
WO2020115200A1 (fr) * 2018-12-07 2020-06-11 Synthon B.V. Procédé amélioré pour la préparation d'ozanimod
WO2020152718A1 (fr) * 2019-01-25 2020-07-30 Mylan Laboratories Limited Formes polymorphes de 5-[3-[(1s)-2,3-dihydro-1-[(2-hydroxyéthyl) amino]-1h-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-(1-méthyléthoxy)benzonitrile
CN112062785B (zh) * 2019-06-11 2023-06-27 广东东阳光药业有限公司 奥扎莫德及其中间体的制备方法
US12404256B2 (en) 2019-07-16 2025-09-02 Synthon B.V. Process for preparing ozanimod
CA3156298A1 (fr) 2019-10-31 2021-05-06 Laetitia POUZOL Combinaison d'un antagoniste de cxcr7 avec un modulateur du recepteur s1p1
US12398112B2 (en) 2020-04-02 2025-08-26 Synthon B.V. Crystalline form of ozanimod hydrochloride
EP4212156A1 (fr) 2022-01-13 2023-07-19 Abivax Combinaison de 8-chloro-n-(4-(trifluorométhoxy)phényl)quinolin-2-amine et de ses dérivés avec un modulateur de récepteur de s1p

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2776242C (fr) 2009-10-08 2014-09-02 Sanofi Derives de phenyloxadiazole en tant qu'inhibiteurs de pgds
PL2498610T5 (pl) 2009-11-13 2024-11-04 Receptos Llc Selektywne modulatory receptora sfingozyno-1-fosforanu i sposoby syntezy chiralnej
WO2015066515A1 (fr) * 2013-11-01 2015-05-07 Receptos, Inc. Modulateurs sélectifs des récepteurs de la sphingosine-1-phosphate et traitement combiné les utilisant
PL3470400T3 (pl) 2016-06-14 2025-08-04 Receptos Llc Krystaliczne postacie ozanimodu i chlorowodorku ozanimodu oraz sposoby ich otrzymywania
CN109563059A (zh) * 2016-08-19 2019-04-02 苏州科睿思制药有限公司 奥扎莫德的晶型及其制备方法
WO2018049632A1 (fr) * 2016-09-14 2018-03-22 杭州领业医药科技有限公司 Forme cristalline d'ozanimod, procédé de préparation et composition pharmaceutique associés
CA3038106A1 (fr) * 2016-09-29 2018-04-05 Celgene International Ii Sarl Composes et methodes pour le traitement de l'inflammation

Also Published As

Publication number Publication date
MA48798A (fr) 2020-04-08
US20200087269A1 (en) 2020-03-19
WO2018215807A1 (fr) 2018-11-29
PT3630738T (pt) 2023-10-24
EP3630738A1 (fr) 2020-04-08
HRP20231308T1 (hr) 2024-04-26
EP3630738A4 (fr) 2021-03-10
HUE064642T2 (hu) 2024-04-28
US12459907B2 (en) 2025-11-04
ES2960051T3 (es) 2024-02-29
SI3630738T1 (sl) 2024-02-29
CN110997645A (zh) 2020-04-10
CN110997645B (zh) 2023-10-10
EA201992421A1 (ru) 2020-03-27
PL3630738T3 (pl) 2024-04-08
EP3630738B1 (fr) 2023-07-19

Similar Documents

Publication Publication Date Title
FR3087439B1 (fr) Procédé pour la préparation de 3α-hydroxy-5α-prégnan-20-one (brexanolone)
PE20221420A1 (es) Procedimiento fotoquimico para la preparacion de (4r,4s)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carboxamida
MA40480B1 (fr) Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
MA41607B1 (fr) Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
TN2015000347A1 (fr) Azabenzimidazoles servant d'inhibiteurs d'isoenzymes pde4 pour le traitement de troubles du snc et d'autres troubles
MA38922A2 (fr) Dérivés de quinolizine substitués utiles en tant qu'inhibiteurs de l'integrase du vih
EP3848382C0 (fr) Intermédiaires pour la production des dérivés des acides biliaires, surtout de l'acide obéticholique
MA38330B1 (fr) Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre)
EA201992421A1 (ru) Способ получения озанимода
NZ746906A (en) Oxaborole esters and uses thereof
MX2017015662A (es) Procesos para la preparacion de derivados acidos de n-acetilgalactosamina (galnac).
MA39983A (fr) Dérivés de carboxamide
BR112018070345A2 (pt) processo para a preparação de derivados de 4-aminoindano e amidas de aminoindano relacionadas
MX2021007511A (es) Procedimiento para la preparacion de anilinas sustituidas.
MA38250B1 (fr) Nouveau dérivés d'hydantoïne pour leurs utilisations dans le traitement de maladies, comme l'osteoporose et la thrombocytopenie
MA58104B1 (fr) Procédé et intermédiaire pour la préparation d'oxétane-2-ylméthanamine
CA3156366A1 (fr) Procede de production d'acides alcanesulfoniques
FR3062851B1 (fr) Procede de preparation monotope de composes organo-iodes
FR3085036B1 (fr) Procede de synthese de la vitamine a
MX2021000226A (es) Nuevo proceso para la preparacion de diamidas antranilicas.
MA41186B1 (fr) Nouvelles formes de cristal du sel monosodique de foramsulfuron
EP3941911A4 (fr) Procédé de synthèse d'acide 2,5-furandicarboxylique
AR120727A1 (es) Composición farmacéutica que comprende bpi-7711 y método de preparación de la misma
EA202191161A1 (ru) Новый способ получения (s)-2-(2-(4-гидроксифенил)ацетамидо)-3-фенилпропановой кислоты